DoD PRMRP Technology/Therapeutic Development Award | W81XWH 22 PRMRP TTDA

Opportunity Information: Apply for W81XWH 22 PRMRP TTDA

The DoD PRMRP Technology/Therapeutic Development Award (TTDA) is a product-focused funding opportunity from the Department of Defense (administered through the U.S. Army Medical Research Acquisition Activity, USAMRAA) designed to move strong preclinical research results toward real-world medical products. The main intent is to support translational work that turns promising early findings into tangible tools that could eventually be used in clinical settings. These products can span a wide range of medical needs, including prevention, detection, diagnosis, treatment, and improvements to quality of life, as long as the disease or condition being addressed fits within one of the FY22 Peer Reviewed Medical Research Program (PRMRP) Topic Areas and aligns with at least one FY22 PRMRP Strategic Goal. A central theme is relevance to the military health mission, meaning proposed products should address healthcare needs that matter to military Service Members, Veterans, and/or their beneficiaries.

This award mechanism is explicitly aimed at technology or therapeutic development, rather than basic discovery science. In practice, that means the government is looking for projects where the science has matured enough to justify development steps that de-risk the product and move it closer to clinical utility. Depending on the project, this often includes activities like refining a prototype or candidate therapeutic, establishing performance characteristics, optimizing formulation or delivery, generating additional preclinical efficacy data, conducting safety or toxicology-related work appropriate to the stage of development, developing manufacturing approaches or quality controls, and completing other milestone-based tasks that support a credible path toward eventual clinical application. The “product-driven” framing signals that reviewers typically expect a clear development plan with measurable deliverables and a realistic trajectory toward use in patients, even if patient testing is not part of the proposed work under this mechanism.

A key boundary in the solicitation is that the TTDA cannot be used to conduct clinical trials. However, it does allow non-interventional clinical research studies, meaning certain human-related research may be permissible if it does not involve testing an intervention in a trial format. This distinction matters for applicants planning validation steps, biomarker work, or observational efforts using existing samples or data. The emphasis remains on generating evidence and development outputs that prepare a product for later-stage evaluation, rather than running a clinical trial during the award period.

Administratively, the opportunity is listed as discretionary funding and can be awarded as either a grant or a cooperative agreement, depending on the level of anticipated government involvement in the project. The posted CFDA number is 12.420, and eligibility is described as “unrestricted,” indicating it is broadly open to a wide range of applicant organizations, subject to any additional constraints that might appear in the full solicitation’s eligibility language. The funding opportunity number is W81XWH-22-PRMRP-TTDA, and it was created on March 16, 2022, with an original closing date of May 27, 2022. The listing indicates an expectation of around 20 awards. The award ceiling is shown as 0 in the source data, which typically means the maximum funding amount is not specified in that particular summary field and would need to be confirmed in the full program announcement or funding restrictions section.

Overall, the TTDA is best understood as a DoD translational development award meant for teams that already have compelling preclinical evidence and a defined product concept, and that can present a structured plan to push that concept through the next development gates. The program’s review lens is likely to prioritize military-relevant impact, alignment with the FY22 PRMRP topic and strategic goal framework, and a practical development strategy that produces a well-justified, clinic-facing product package without conducting an interventional clinical trial.

• The Department of Defense, Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DoD PRMRP Technology/Therapeutic Development Award" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on Mar 16, 2022.
• Applicants must submit their applications by May 27, 2022. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 20 candidate(s).
• Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.

Apply for W81XWH 22 PRMRP TTDA

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: